RAPT Therapeutics, Inc. (RAPT) Dividend History

Company News

• RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

  RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of two new directors to its board. The company's lead product candidate, RPT904, is in late-stage development for treating allergic diseases.

  GlobeNewswire Inc.
• Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data - Zacks Investment Research

  Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival benefit.

  Zacks Investment Research

  Featured Companies: ADPT AGEN ANIP
• Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

  U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday. Shares of Rivian Automotive, Inc. (NASDAQ: RIVN) fell sharply in today’s pre-market trading after the company reported a wider-than-expected loss for its fourth quarter and announced plans to reduce its salaried workforce by around 10% to help further improve costs. The company said it sees production of 57,000 vehicles in 2024. Rivian Automotive shares dipped 14.3% to $13.17 in pre-market trading. Here are some big ...

  Benzinga

  Featured Companies: ETSY LCID NOVA RIVN RUN
• RAPT Therapeutics’ stock plunges as FDA halts two clinical trials

  RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation drug.

  MarketWatch